Detail page

Knowledge Web

Person

Richard Friedrich Schlenk (1965-)

Internist

Name	Richard Friedrich Schlenk
Time	1965- (Date of birth and death)
Place	Kirchheim unter Teck (Geburtsort) Heidelberg (Wirkungsort) Deutschland
Academic degree	Prof. Dr. med.
Profession	Internist (characteristic profession)
Variant	Richard F. Schlenk R. F. Schlenk Richard Schlenk R. Schlenk
Related	Nationales Centrum für Tumorerkrankungen
Further information	Habil. Fach Innere Medizin an der Univ. Ulm Leiter der NCT Studienzentrale, Heidelberg
Record type	Person
GND-Identifier	129025380
Record ID	129025380
Involved in show all Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease Predicting Successful Hematopoietic Stem Cell Collection in Healthy Allogeneic Donors Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial Atypical presentation of patients with chronic myeloid leukemia in chronic phase : Case report Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia Palbociclib in acute leukemias with KMT2A-rearrangement: results of AMLSG 23-14 trial Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO Post-Induction Treatment for Acute Myeloid Leukemia: Something Change? Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q) Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial Adjusting Simon's optimal two‐stage design for heterogeneous populations based on stratification or using historical controls Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study Defective homologous recombination DNA repair as therapeutic target in advanced chordoma Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine Targeting FLT3 mutations in AML: review of current knowledge and evidence Defective homologous recombination DNA repair as therapeutic target in advanced chordoma Management of patients with acute promyelocytic leukemia Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia Precision oncology based on omics data: the NCT Heidelberg experience All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study Akute myeloische Leukämie beim älteren Patienten Identifying prognostic SNPs in clinical cohorts: complementing univariate analyses by resampling and multivariable modeling Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials Prognostische und prädiktive Bedeutung genomischer Veränderungen bei der akuten myeloischen Leukämie Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials Aktivität von Thrombozyten und deren Interaktion mit neutrophilen Granulozyten bei Patienten mit Polymyalgia rheumatica

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Richard Friedrich Schlenk (1965-)

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease

Predicting Successful Hematopoietic Stem Cell Collection in Healthy Allogeneic Donors

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

Atypical presentation of patients with chronic myeloid leukemia in chronic phase : Case report

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

Palbociclib in acute leukemias with KMT2A-rearrangement: results of AMLSG 23-14 trial

Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

Post-Induction Treatment for Acute Myeloid Leukemia: Something Change?

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial

A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial

Adjusting Simon's optimal two‐stage design for heterogeneous populations based on stratification or using historical controls

Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine

Targeting FLT3 mutations in AML: review of current knowledge and evidence

Defective homologous recombination DNA repair as therapeutic target in advanced chordoma

Management of patients with acute promyelocytic leukemia

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)

Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

Precision oncology based on omics data: the NCT Heidelberg experience

All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study

Akute myeloische Leukämie beim älteren Patienten

Identifying prognostic SNPs in clinical cohorts: complementing univariate analyses by resampling and multivariable modeling

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials

Prognostische und prädiktive Bedeutung genomischer Veränderungen bei der akuten myeloischen Leukämie

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials

Aktivität von Thrombozyten und deren Interaktion mit neutrophilen Granulozyten bei Patienten mit Polymyalgia rheumatica